Replies to post #514242 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

LOL, more bullshit addressed here:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169961535

[Dr Bala]

OS: essential: the P3 trial has outstanding OS.
PFS: not essential.

[SkyLimit2022]

You are correct— Dr. Liau wrote a brilliant paper in 2018 and her next big DCVax updated analysis in light of the complete data set with the advantage of more that four additional years of patients data is forthcoming.

Dr. Liau has authored over 170 peer-reviewed research articles, along with several book chapters, and a textbook entitled Brain Tumor Immunotherapy. She is on the editorial boards of several scientific/medical journals and was the Editor-in-Chief of the Journal of Neuro-Oncology (2007–2017).

She will also present at SNO:

https://soc-neuro-onc.org/

https://virtualtrials.org/dcvax.cfm

[Dr Bala]

The Liau protocol will replace the Stupp protocol. The helmet will no longer be the SOC.

[SkyLimit2022]

Thank for bringing awareness to the current UCLA Keytruda—DCVax study for rGBM.

https://www.merck.com/stories/fighting-cancer-requires-an-open-mind/

Merck: “Personalized cancer vaccines which are therapeutic vaccines based on patients’ specific cancer that could potentially prime the immune system to recognize certain characteristics and attack the cancer cells”

DCVax is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40

NCI, Merck, & PHASE ONE are today supporting collaborators on the UCLA Keytruda trial—100% of patients in both the experimental group AND the placebo group receive DCVax. Only Keytruda in combo is being investigated—everyone receives DCVax as if it were SOC.

Group A (pembrolizumab, ATL-DC, poly ICLC)
Beginning 14 days prior to scheduled surgery, patients receive pembrolizumab IV over 30 minutes. After surgery, patients receive pembrolizumab IV over 30 minutes on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.

Group B (placebo, ATL-DC, poly ICLC)
Beginning 14 days prior to scheduled surgery, patients receive placebo IV. After surgery, patients receive placebo IV on day 1. Cycle repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive ATL-DC ID with poly ICLC IM every 2 weeks for up to 3 doses in the absence of disease progression or unacceptable toxicity.

virtualtrials.org/dcvax.cfm

https://clinicaltrials.gov/ct2/show/NCT04201873

[Dr Bala]

The helmet will be replaced by the DCVax-L therapy for the new SOC.